# Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism

> **NCT01446042** · PHASE3 · COMPLETED · sponsor: **Acerus Pharmaceuticals Corporation** · enrollment: 306 (actual)

## Conditions studied

- Male Hypogonadism

## Interventions

- **DRUG:** Testosterone
- **DRUG:** Testosterone

## Key facts

- **NCT ID:** NCT01446042
- **Lead sponsor:** Acerus Pharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2012-12
- **Final completion:** 2013-03
- **Target enrollment:** 306 (ACTUAL)
- **Last updated:** 2018-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01446042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01446042, "Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01446042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*